Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Metastatic Breast Cancer Clinical Trial

Official title:

A Multicenter, Phase II Open Label Study of Pyrotinib Maleate Combined With Docetaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03876587
• Other study ID #: HR-BLTN-001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 2019
• Est. completion date: December 2020

Study information

• Verified date: March 2019
• Source: Zhejiang Cancer Hospital
• Contact: Xiaojia Wang, PhD
• Phone: 86 13906500190
• Email: wxiaojia0803[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the efficacy and safety of pyrotinib combined with docetaxel regimen in the first-line treatment of HER2-positive metastatic breast cancer.

Description:

A multi-center, one-arm, open label design study,which is planned to enroll 79 patients with HER2-positive metastatic breast cancer receiving first-line treatment with pyrotinib and docetaxel. The main purpose of this study was to observe the efficacy and safety of first-line treatment with pyrrolidine and docetaxel for HER2-positive metastatic breast cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 79
• Est. completion date: December 2020
• Est. primary completion date: October 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed histologically.

• HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline).

• do not chemotherapy for recurrent and metastatic lesions, but local treatment for local symptoms, such as radiotherapy for relieving bone pain, is allowed.

• if the patient is bilateral breast cancer, metastasis lesions must be HER2-positive.

• 18-70 years old.

• ECOG PS 0~1.

• life expectancy is not less than 12 weeks.

• at least one measurable lesion according to RECIST 1.1.

• Endocrine therapy is allowed to relapse/metastasis disease; patients with previous adjuvant/neoadjuvant use of Taxus and trastuzumab, disease-free interval from the end of last adjuvant/neoadjuvant Taxus therapy to the progression of tumors (=12 months), and disease-free interval from the end of last adjuvant/neoadjuvant trastuzumab to the progression of tumors (= 6 months).

• ANC = 1.5×109/L,PLT = 75×109/L,Hb = 100 g/L;TBIL=1.0ULN;ALT and AST=3×ULN(ALT and AST=5×ULN if liver metastasis);BUN and Cr=1.5×ULN and CCr=50 mL/min.

• LVEF = 50% and QTc=480 ms.

• known hormone receptor status.

• Signed informed

Exclusion Criteria:

• Central nervous system metastasis.

• Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption.

• patient who received radiotherapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks before admission; those who received anti-tumor endocrine therapy after screening period

• Participated in other drug clinical trials within 4 weeks before admission

• Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have been used or are being used in the past.

• Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.

• Receive other antitumour treatment at the same time

• A history of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired, congenital immunodeficiency disorders, or organ transplantation, is known.

• Has suffered from any heart disease

• Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial

• According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).

• The patient did not recover from the toxicity of previous treatment to grade 0-1 (except hair loss).

• History of neurological or psychiatric disorders

• Along with CYP3A4 inhibitors or inducers or drugs that are using to prolong the QT interval

• Researchers believe that patients are not suitable for any other situation in this study.

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• Pyrotinib Maleate combine with Docetaxel
Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer

Locations

Country	Name	City	State
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang

Sponsors (2)

Lead Sponsor	Collaborator
Zhejiang Cancer Hospital	Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	adverse event	Adverse events are described in terms of CTC AE 5.0	from enrollment to 30 days after the last dose administrate
Primary	Objective Response Rate	Ratio of CR and PR in all subjects	from enrollment to progression or death (for any reason), assessed up to 100 months
Secondary	PFS	Progression-Free Survival	from enrollment to progression or death (for any reason),assessed up to 100 months
Secondary	DoR	Duration of Response	The first evaluation of CR or PR to progression or death (for any reason),assessed up to 100 months
Secondary	Clinical Benefit Rate	Ratio of CR,PR and SD greater than or equal to 24 weeks in all subjects	from enrollment to progression or death (for any reason),assessed up to 100 months
Secondary	OS	Overall Survival	from enrollment to death (for any reason).assessed up to 100 months